February 12, 2008 - Accuray Inc. today announced that two- and thee-year studies on its Cyberknife radiosurgery has shown no side effects on men treated for prostate cancer and prostate specific antigen (PSA) levels showed sustained reduction during the studies.
These findings were shared at the 7th Annual CyberKnife Users' Meeting, which was held Jan. 23-27, 2008 in Scottsdale, AR.
"We're pleased that so much progress has been made demonstrating positive outcomes using the CyberKnife System as a noninvasive treatment option for prostate cancer, including durable PSA level reductions up to three years post-treatment," said Michael Santoro, M.D., attending urologist at Winthrop University Hospital's CyberKnife Radiosurgery Center.
Additionally lung cancer treatment using the CyberKnife System continued to draw a large amount of interest among the attendees with the presentation of experiences from clinicians around the world treating patients with lung tumors successfully with the CyberKnife System, said the company. During the meeting, a majority of the institutions present expressed strong interest in the prospective clinical study that is being led by M. D. Anderson Cancer Center in Houston comparing treatment outcomes with the CyberKnife System versus surgery in early-stage, operable lung cancer, according to Accuray.
Along with the enthusiasm around CyberKnife extracranial treatment results, the system remains a widely accepted tool in the treatment of brain tumors said the company. A data comparison of patients with acoustic tumors, treated by either CyberKnife or Gamma Knife radiosurgery demonstrated superior hearing preservation in the patients treated with the CyberKnife System.
According to the company, emerging CyberKnife treatment applications highlighted at the meeting demonstrated promising results treating patients with breast cancer, bone cancer, kidney cancer and various pain syndromes.
For more information: www.accuray.com
